News
Groupe 39

Nosopharm welcomes new members to supervisory board

11/07/2022

Jacques Dumas appointed chairman of supervisory board, joined by new members Laurent Fraisse, Sandra Dubos and Martin Lauriot Prevost Lyon, France, July 11, 2022 – Nosopharm, specialized in exploring unconventional sources of antibiotics, to discover new drugs to fight antimicrobial resistance, today announces several changes to its supervisory board: Jacques Dumas has been appointed as chairman, taking over from Jacques Biton. Laurent Fraisse is replacing Marie-Paule Richard as an independent member and Sandra Dubos joins as

learn more

NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502 

08/06/2022

An important milestone has been reached for the GNA NOW Consortium with the completion of the GLP toxicology studies for the NOSO-502 program. The results allow for the further development of the program to Phase 1  Utrecht, the Netherlands, and Lyon, France, 8 June 2022  Nosopharm, a biotechnology company specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces the completion and positive results of toxicology studies for

learn more

Nosopharm signs strategic partnership with INRAE and the university of Montpellier

15/03/2022

Collaboration aims to produce chemical libraries of bioactive molecules that will feed into Nosopharm’s anti-infective screening procedures Nosopharm and its partner, the DGIMI laboratory (UMR INRAE—University of Montpellier), hope to establish joint laboratory in 2023 Lyon, France, March 15, 2022—Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces that it has signed a collaboration agreement with the DGIMI laboratory (UMR1333: Diversity, Genomes and Insects-Microorganisms Interactions). DGIMI

learn more

news

Subscribe to our newsfeed

partnering opportunities

Nosopharm is open to synergistic collaborations for the development of its pipeline and the progress of its promising drug discovery programs.

Our goal is to explore, with an industrial partner, the drug discovery potential of Photorhabdus and Xenorhabdus bacteria for human and animal health in any therapeutic indication. Our innovative anti-infective drug discovery platform is based on the exploitation of these two antimicrobial-producing bacteria; Nosopharm is the only biotech company to explore these. Nosopharm is also interested in gaining access to new strains of Photorhabdus and Xenorhabdus or related bacteria, in compliance with the Nagoya Protocol.

To explore partnering opportunities with Nosopharm, please contact us.

Contact us

Nosopharm is an innovative biotechnology company specialized in exploring the microbial biodiversity of the genera Photorhabdus and Xenorhabdus to develop new drugs infectious diseases.

sitemap

Linkedin-in Twitter

Careers

Discover our job and internship opportunities

Join us